Delhi HC allows Biocon, Mylan to sell biosimilar cancer drug Trastuzumab3 min read . Updated: 04 Mar 2017, 01:09 PM IST
Delhi HC quashes Roche's challenge, allows Biocon and Mylan to sell biosimilar drug for metastatic breast cancer, early breast cancer and metastatic gastric cancer
New Delhi: The Delhi high court on Friday gave a green signal to pharmaceutical companies Biocon and Mylan to manufacture and sell its biosimilar drug Trastuzumab for early breast cancer and metastatic gastric cancer.
Select your Category